Nabota Phase 3 trials in China achieve meaningful results

Home > Business > Industry

print dictionary print

Nabota Phase 3 trials in China achieve meaningful results

Daewoong Pharmaceutical's Nabota. [DAEWOONG PHARMACEUTICAL]

Daewoong Pharmaceutical's Nabota. [DAEWOONG PHARMACEUTICAL]

Daewoong Pharmaceutical said Wednesday its Nabota botulinum toxin demonstrated statistically meaningful results in Phase 3 trials in China, signaling an imminent entry to the market, the second largest botulinum toxin market in the world.
 
Nabota is a treatment for wrinkles and was first introduced in Korea in 2014. Nabota acquired approval from the U.S. Food and Drug Administration in 2018 and is currently sold under the name Jeuveau in the United States.
 
According to the company, a total of 473 patients with moderate and severe symptoms took part in the Phase 3 clinical trials. Volunteers were treated once with either Nabota or the placebo.
 
A phase 3 clinical trial is the last round of clinical trials required for the drug.
 
The most important data set in proving efficacy was to reduce forehead wrinkles. The company tracked the patients’ situation for 16 weeks at four-week intervals.
 
Four weeks after injection, people treated with Nabota showed about 92.2 percent of improvement in forehead wrinkles while people treated with the placebo showed 86.8 percent.
 
Daewoong aims to introduce the product in Chinese market by the end of 2022.
  
“The Chinese market is considered having high potential for growth as only 1 percent of people there have used botulinum toxin so far,” said Park Seong-soo, head of Nabota business division in Daewoong Pharmaceutical. “The company will push hard to introduce the product in the Chinese market in 2022, and aims to become the No. 1 company in terms of sales in three years.”
 
China is the second largest botulinum toxin market after the United States. The size of botulinum toxin market in China, which was about $672 million in 2018, is expected to grow to $1.56 billion in 2025, according to data from Goldman Sachs.

BY SARAH CHEA [chea.sarah@joongang.co.kr]
Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
s
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now